Published in Oncotarget on March 10, 2015
Combination therapy with TLR7 agonist and radiation is effective for the treatment of solid cancer. Ann Transl Med (2016) 0.75
A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial). BMC Cancer (2015) 0.75
LDB1 overexpression is a negative prognostic factor in colorectal cancer. Oncotarget (2016) 0.75
Intercellular Communication of Tumor Cells and Immune Cells after Exposure to Different Ionizing Radiation Qualities. Front Immunol (2017) 0.75
TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities. Oncoimmunology (2015) 0.75
Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol (2017) 0.75
UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. PLoS One (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
Taking dendritic cells into medicine. Nature (2007) 11.82
"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 7.61
Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest (2005) 5.00
Colorectal cancer. Lancet (2005) 4.90
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol (2013) 3.56
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood (2009) 2.01
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood (2012) 1.92
A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol (2008) 1.68
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest (2012) 1.45
Radiation and immunotherapy: a synergistic combination. J Clin Invest (2013) 1.44
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol (2006) 1.31
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg (2006) 1.31
IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol (1989) 1.28
CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol (2004) 1.26
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun (2004) 1.15
Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett (2013) 1.07
In situ photoimmunotherapy: a tumour-directed treatment for melanoma. Br J Dermatol (2006) 1.05
Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses. J Immunol (1998) 1.05
Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol (2012) 1.04
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. Int J Cancer (2014) 0.95
Antiviral applications of Toll-like receptor agonists. J Antimicrob Chemother (2012) 0.90
Interleukin-6 is produced by epidermal cells and plays an important role in the activation of human T-lymphocytes and natural killer cells. Ann N Y Acad Sci (1989) 0.86
NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother (2008) 0.85
Clearance of invasive melanoma with topical imiquimod. J Drugs Dermatol (2013) 0.85
Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies. Immunotherapy (2013) 0.84
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J (2011) 0.83
Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide. Cancer Biol Ther (2010) 0.81
In vivo depletion of CD4- and CD8-specific T cells. Curr Protoc Immunol (2001) 0.80
Differential indirect activation of human invariant natural killer T cells by Toll-like receptor agonists. Immunotherapy (2009) 0.79
'Rub on' treatment for basal-cell carcinoma. Lancet Oncol (2002) 0.78